Anna Wingate

Plasma <i>AR</i> and abiraterone-resistant prostate cancer

Alessandro Romanel, Delila Gasi Tandefelt, Vincenza Conteduca et al. · Science Translational Medicine · 2015 · 441 citations · Full text

Medicine, Oncology, Pharmacology +14

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

Vincenza Conteduca, Daniel Wetterskog, Mansour T. A. Sharabiani et al. · Annals of Oncology · 2017 · 269 citations · Full text

Medicine, Oncology, Pharmacology +17

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100

Juliet Richards, Ai Chiin Lim, C. R. M. Hay et al. · Cancer Research · 2012 · 261 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Genome-wide plasma DNA methylation features of metastatic prostate cancer

Anjui Wu, Paolo Cremaschi, Daniel Wetterskog et al. · Journal of Clinical Investigation · 2020 · 105 citations · Full text

Medicine, Genetics, Oncology +17

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial

Anuradha Jayaram, Anna Wingate, Daniel Wetterskog et al. · Annals of Oncology · 2021 · 61 citations · Full text

Medicine, Oncology, Pharmacology +17